Search

Search results

373 results found

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. PMID: 37497384

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18:145-154.

Prevalence of Dyskinesia and OFF by 30-minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.